166 related articles for article (PubMed ID: 6357266)
1. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Bataille R; Durie BG; Grenier J
Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
[TBL] [Abstract][Full Text] [Related]
2. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.
Cimino G; Avvisati G; Amadori S; Cava MC; Giannarelli D; Di Nucci GD; Magliocca V; Petrucci MT; Poti G; Sgadari C
Br J Haematol; 1990 Jul; 75(3):373-7. PubMed ID: 2386771
[TBL] [Abstract][Full Text] [Related]
3. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
4. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy.
Bartl R; Frisch B; Diem H; Mündel M; Fateh-Moghadam A
Eur J Haematol Suppl; 1989; 51():88-98. PubMed ID: 2697597
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
10. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
Bataille R; Grenier J; Sany J
Blood; 1984 Feb; 63(2):468-76. PubMed ID: 6362753
[TBL] [Abstract][Full Text] [Related]
11. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
13. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
[TBL] [Abstract][Full Text] [Related]
15. Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.
Bataille R; Magub M; Grenier J; Donnadio D; Sany J
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):59-66. PubMed ID: 6177535
[TBL] [Abstract][Full Text] [Related]
16. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
Jacobson JL; Hussein MA; Barlogie B; Durie BG; Crowley JJ;
Br J Haematol; 2003 Aug; 122(3):441-50. PubMed ID: 12877671
[TBL] [Abstract][Full Text] [Related]
17. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.
Bartl R; Frisch B; Diem H; Mündel M; Nagel D; Lamerz R; Fateh-Moghadam A
Cancer; 1991 Nov; 68(10):2241-50. PubMed ID: 1913461
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic implications of myeloma staging.
Durie BG; Bataille R
Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Cuzick J; Cooper EH; MacLennan IC
Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
